Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where F. Lanzi is active.

Publication


Featured researches published by F. Lanzi.


European Urology | 2009

Histopathologic Analysis of Peritumoral Pseudocapsule and Surgical Margin Status after Tumor Enucleation for Renal Cell Carcinoma

Andrea Minervini; Claudio Di Cristofano; A. Lapini; Marco Marchi; F. Lanzi; Gianluca Giubilei; N. Tosi; A. Tuccio; Massimiliano Mancini; Carlo Della Rocca; Sergio Serni; Generoso Bevilacqua; Marco Carini

BACKGROUND The oncologic safety of blunt tumor enucleation (TE) of renal cell carcinoma (RCC) depends on the presence of a continuous pseudocapsule (PS) around the tumor and on the possibility of obtaining negative surgical margins (SMs). OBJECTIVE To investigate the PS and SMs after TE to define the real need to take a rim of healthy parenchyma around the tumor to avoid the risk of positive SMs. The risk of PS invasion related to other clinical and pathologic variables was also evaluated. DESIGN, SETTING, AND PARTICIPANTS Between September 2006 and December 2007, data were gathered prospectively from 187 consecutive patients who had kidney surgery. Overall, 90 consecutive patients who had TE for RCC were eligible for the study. All specimens were evaluated using an image analyzer by a dedicated uropathologist. INTERVENTION TE was done by blunt dissection using the natural cleavage plane between the tumor and the normal parenchyma. MEASUREMENTS PS, SM, and routinely available clinical and pathologic variables were recorded. RESULTS AND LIMITATIONS In 60 RCC tumors (67%) the PS was intact and free from invasion (PS-) while in 30 (33%) there were signs of penetration within its layers, with or without invasion beyond it. Indeed, 26.6% had PS that had been penetrated on the parenchymal side and 6.6% had penetration on the perirenal fat tissue side. The odds of having PS penetration increased significantly with an increase in clinical tumor size. PS penetration was also significantly associated with pathologic tumor dimensions and grade. In all cases the SMs were negative after TE. The present patients, followed for >2 yr, will enable us to correlate the risk of local recurrence with PS status. CONCLUSIONS The risk of PS penetration is associated with clinical and pathologic tumor dimensions and grade. If there is PS invasion into normal parenchyma, the presence of a thin layer of tissue allows for negative SM even if a TE is performed.


BJUI | 2007

Simple enucleation for the treatment of renal angiomyolipoma

Andrea Minervini; Gianluca Giubilei; L. Masieri; F. Lanzi; Sergio Serni; Marco Carini

To report on the role of simple enucleation for treating renal angiomyolipoma (AML) in a series of patients treated in our department.


Urologia Internationalis | 2010

Prognostic Role of Perineural Invasion in 239 Consecutive Patients with Pathologically Organ-Confined Prostate Cancer

L. Masieri; Michele Lanciotti; Gabriella Nesi; F. Lanzi; N. Tosi; Andrea Minervini; A. Lapini; Marco Carini; Sergio Serni

Objective: The aim of our study was to analyze the role of perineural invasion (PNI) as a predictive parameter of outcome after radical prostatectomy (RRP) in pathologically organ-confined prostate cancer (PCa) and to assess its possible correlation with other well-known prognostic features. Patients and Methods: At our institution between January 2000 and December 2007, we prospectively collected data from 251 consecutive patients with pathologically localized PCa after antegrade RRP. In our analysis 239 patients were included. PNI was defined as adenocarcinoma within the perineural space adjacent to a nerve. We evaluated the biochemical progression-free survival rate using the Kaplan-Meier method to establish the correlation between PNI and prognosis, the log-rank test to verify the statistical significance, and χ2 test to investigate the correlation between PNI and other clinicopathological parameters. Results: We found intraprostatic PNI in 157 patients (65.7%). The PNI rate was 73% (149/204) in pT2b–c vs. 26% (8/35) in pT2a surgical specimens (p < 0.001), and it was 78.5% (73/93) in patients with a Gleason score of 7–10 vs. 57% (84/146) in a Gleason score of 2–6 (p < 0.01). The mean follow-up was 65.4 (median 62, range 24–118) months. Overall, 11/239 (4.6%) patients presented biochemical recurrence after surgery and 7 (63.6%) of these patients showed PNI, but this was not statistically higher than in patients free from progression (150/228, 65.7%). The actuarial biochemical progression-free survival rate for all patients was 96.9 and 93.5% at 60 and 84 months, respectively, and the stratification based on the presence or absence of PNI did not allow us to identify different prognostic groups. Conclusions: Perineural infiltration frequently takes part in the pathway of extraprostatic extension. In our series, patients with pathological T2 stages and PNI were found to present a higher pT2 stage and Gleason score, even though our early biochemical-free outcome was not significantly higher than in patients without PNI.


Ejso | 2009

Multiple ipsilateral renal tumors: Retrospective analysis of surgical and oncological results of tumor enucleation vs radical nephrectomy

Andrea Minervini; Sergio Serni; Gianluca Giubilei; F. Lanzi; Gianni Vittori; A. Lapini; Marco Carini

AIMS To evaluate the role of nephron-sparing surgery (NSS) compared to radical nephrectomy (RN) for treating multiple ipsilateral renal tumors. METHODS We retrospectively reviewed the clinical and pathological data of 960 patients who had surgery for pathologically confirmed RCC between 1986 and 2006. Thirty-four patients were diagnosed as having at least one ipsilateral smaller solid lesion associated with the primary RCC: 22 had RN while 12 had NSS for tumor enucleation. RESULTS All patients who had NSS had tumors confined within the kidney, as did 82% of patients treated with RN. The sole presence of concomitant accompanying benign histology to the primary RCC was diagnosed in 20% of patients. The mean (median, range) follow-up for patients treated with RN and NSS was 69 (58, 12-214) and 58 (44, 12-151) months. Tumor stage was significantly associated with tumor-specific survival (TSS) in the RN group (p<0.001). None of the patients who had tumor enucleation had positive surgical margins. Two patients recurred locally after NSS, elsewhere in the kidney, resulting in a crude ipsilateral recurrence rate of 17%. The analysis of TSS for patients with multiple ipsilateral tumors with a pT1 primary lesion showed no statistically significant differences between patients who had RN or NSS. Two patients had contralateral recurrence, resulting in a crude rate of 6%. CONCLUSIONS For patients with multiple ipsilateral renal tumors, 20% of the satellite lesions are benign and 6% develop a contralateral metachronous recurrence. We also observed similar TSS for patients treated with NSS and RN.


Applied Immunohistochemistry & Molecular Morphology | 2012

A proposed score for assessing progression in pT1 high-grade urothelial carcinoma of the bladder.

Maria Rosaria Raspollini; Andrea Minervini; A. Lapini; F. Lanzi; Matteo Rotellini; Gianna Baroni; Marco Carini

We tested a selected series of patients with single urothelial high-grade pT1 stage (pT1 HG) or urothelial carcinoma in situ (CIS) with a set of immunohistochemical markers to elaborate a risk score for progression. We retrospectively reviewed all first diagnoses of single, <3 cm, urothelial papillary carcinoma pT1 HG or isolated CIS between 2006 and 2009. Galectin-3, CD44, E-cadherin, CD138, p16, survivin, HYAL-1, and topoisomerase-II &agr; were used. A grading score 0 or 1 for each immunohistochemical staining was assigned to obtain a total score for assessing the progression. The median “progression score” was selected as cutoff value for statistical analysis. Overall, 23 patients (19 pT1 HG and 4 CIS) were included in the study. After a median follow-up of 21 months (range, 12 to 34 mo), 9 patients (39.1%) showed disease recurrence whereas 4 patients (17.4%) showed tumor progression. Topoisomerase-II &agr;, p16, survivin, galectin-3, and CD138 were significantly associated with progression. Progression score ranged from 0 (best prognosis) to 7 (worst prognosis). Using a score ≥5 as a threshold, specificity was 78.9%, sensitivity 100%, positive predictive value 50%, and negative predictive value 100%. ROC area (a 95% confidence interval, 0.807-1.000; P<0.001). This immunohistochemistry-based progression score using a threshold ≥5, might help the clinician to focus on patients with HG pT1 or extended CIS at high risk for disease progression. These patients might benefit from a more intensive follow-up program or early cystectomy.


Rivista Urologia | 2018

Perineal schwannoma: an unusual tumor and clinical presentation – first case with erectile dysfunction associated with this neoplasm

Filippo Cecconi; Giuseppe Maiolino; F. Lanzi; Gianni Vittori; Filippo Gentile; Gerardo Pizzirusso; Gabriele Barbanti; Sergio Tripodi

Introduction: Perineal schwannomas (PS) are very rare benign tumors with few cases reported in literature and none of these reports erectile dysfunction among clinical presentations. Case description: We report a case of PS with unusual clinical presentation showing erectile dysfunction associated with perineal pain and discomfort during defecation, and the postoperative residual pain and erectile dysfunction treatment. Conclusions: On the basis of a literature review of all cases reported and on our case reported, we have delineated a clinical, diagnostic, and therapeutic profile of PS, summarized in a useful table.


Archivio italiano di urologia, andrologia | 2009

Review of the current status of tumor enucleation for renal cell carcinoma.

Andrea Minervini; A. Tuccio; A. Lapini; F. Lanzi; Gianni Vittori; Giampaolo Siena; N. Tosi; Sergio Serni; Marco Carini


International Urology and Nephrology | 2012

The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml

L. Masieri; Andrea Minervini; Gianni Vittori; Michele Lanciotti; F. Lanzi; A. Lapini; Marco Carini; Sergio Serni


European Urology Supplements | 2012

970 Clinical and pathological outcome after radical and nerve sparing anterograde prostatectomy for bioptic Gleason score ≥ 7 and PSA ≥ 10 ng/ml

Michele Lanciotti; L. Masieri; C. Giannessi; S. Giancane; F. Lanzi; Gianni Vittori; G. Vignolini; Andrea Minervini; A. Lapini; Marco Carini; Sergio Serni


European Urology Supplements | 2012

77 Newly onset hyperparathyroidism during sunitinib administration in mRCC patients

A. Lapini; V. Baldazzi; R. Tassi; F. Lanzi; L. Masieri; Marco Carini; R. Mazzanti

Collaboration


Dive into the F. Lanzi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Lapini

University of Florence

View shared research outputs
Top Co-Authors

Avatar

L. Masieri

University of Florence

View shared research outputs
Top Co-Authors

Avatar

N. Tosi

University of Florence

View shared research outputs
Top Co-Authors

Avatar

A. Tuccio

University of Florence

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge